INTRODUCTION
============

Neoadjuvant chemotherapy (NAC) has become a standard treatment for the triple-negative and human epidermal growth factor receptor 2 (HER2)-positive breast cancer subtypes^([@r1],[@r2])^. Although its predicted outcomes are similar to those of adjuvant therapy, NAC has certain advantages, such as reducing the tumor burden, downstaging axillary nodal disease, and allowing early assessment of tumor response, as well as *in vivo* assessment of tumor biology^([@r1]-[@r4])^. It also provides some prognostic information: patients who achieve a pathological complete response (pCR) after NAC have been shown to have better survival rates^([@r1],[@r2],[@r5])^.

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has been widely used in evaluating the response to NAC, allowing accurate measurement of tumor size at each stage of treatment^([@r4],[@r6])^. However, it provides not only morphological information but also functional information, through the evaluation of the many factors affecting contrast uptake by the tumor and normal breast tissue^([@r7]-[@r9])^. One of the main parameters evaluated in DCE-MRI is background parenchymal enhancement (BPE).

The definition of BPE is enhancement of the normal fibroglandular tissue of the breast parenchyma that appears when contrast is used in MRI ([Figure 1](#f1){ref-type="fig"}), and the BPE can be described as minimal, mild, moderate, or marked^([@r10])^. It is dynamic and can vary from woman to woman, as well as in a particular woman over time. It correlates with the vascularization of tissue and with its permeability to the contrast agent. Situations that alter these conditions potentially alter contrast uptake^([@r11])^, and several factors can influence the enhancement of breast tissue, pathological or not, focally or diffusely.

Figure 1**A**: Pre-NAC contrast-enhanced sagittal DCE-MRI sequence showing a nodule with a mildly irregular form and ill-defined margins, with heterogeneous internal enhancement (invasive ductal carcinoma proven by core biopsy). **B**: Post-NAC contrast-enhanced sagittal DCE-MRI sequence not showing the previous nodule in which a pCR, according to the Response Evaluation Criteria in Solid Tumors criteria, was achieved.

Various studies have tried to find ways to predict the response to adjuvant chemotherapy and NAC, with the purpose of enabling personalization of cancer treatment^([@r2],[@r3],[@r12],[@r13])^. Many such studies have chosen the contralateral breast for this evaluation, in an attempt to avoid misinterpretation caused by the presence of the tumor in the affected breast. Whether the appearance of the BPE and the treatment response differ between the affected breast and the contralateral breast is an open question.

In this study, we aimed to investigate BPE in women with primary unilateral breast cancer who received NAC. To that end, we compared the BPE features, in both breasts, before and after NAC.

MATERIALS AND METHODS
=====================

This was a retrospective, cross-sectional observational study conducted at a teaching breast care center and at a private breast imaging clinic. The study was approved by the local research ethics committee (Reference no. 2.079.528), and the patients gave written informed consent for the use of the images.

We evaluated a consecutive sample of women with invasive breast cancer who were selected to undergo NAC and who underwent DCE-MRI before and after the NAC. The study, which was conducted between January 2016 and September 2017, included women who had undergone breast MRI examinations between July 2007 and July 2017.

The inclusion criteria were having been selected to undergo NAC and the results of breast DCE-MRI performed before and after NAC being available in our radiology information system and picture archiving and communication system databases. The exclusion criteria were having a history of unilateral or bilateral mastectomy and having bilateral breast cancer.

The sample size was calculated to achieve a level of significance of 5% (α = 0.05 for a type I error) and a power of 80% (β = 0.20 for a type II error). The minimum sample size required was thus found to be n = 82.

MRI technique
-------------

All DCE-MRI examinations of the breast were performed in a 1.5-T scanner (Achieva; Philips Medical Systems, Best, the Netherlands), with a double phased-array dedicated breast coil and the patient in the prone position. The imaging protocol included multiplanar acquisition of 0.6-mm and 4.5-mm slices in T1-weighted and T2weighted short-tau inversion-recovery, maximum intensity projection, and dynamic sequences. Bilateral sagittal T1-weighted sequences with fat saturation were acquired with the following parameters: a repetition time of 5.1 ms; an echo time of 2.3 ms; a flip angle of 10°; a 512 × 512 matrix; and a sensitivity encoding factor of 2. Images were acquired once prior to and three times after a bolus injection of 0.1 mmol/kg of gadobutrol (Dotarem; Guerbet, Roissy, France) or gadoteridol (ProHance; Bracco, Milan, Italy), which was followed by a 30 mL saline flush, digital subtraction, dynamic curve analysis, and acquisition of high-resolution isotropic sequences (in thin sections, in T1 weighting with fat saturation).

Analysis of BPE
---------------

We classified BPE (assessed on the first contrast-enhanced image, with fat suppression and digital subtraction, at approximately 90 s after contrast administration) in accordance with the American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) Atlas, 5th edition, without quantitative calculations, as in everyday clinical practice. Both breasts were evaluated ([Figure 1](#f1){ref-type="fig"}). Because the images were obtained in isotropic sequences, the BPE may be evaluated on sagittal and axial images, although the latter results in better evaluation of BPE symmetry. We evaluated the level and symmetry of BPE, as well as its relationship with clinical and imaging features ([Figures 2](#f2){ref-type="fig"} and [3](#f3){ref-type="fig"}). The criteria established in the St. Gallen/Vienna 2015 consensus^([@r14])^ were used in order to classify molecular subtypes. The pre-NAC tumor size on MRI was categorized based on a receiver operating characteristic (ROC) curve for achieving a pCR ([Figure 4](#f4){ref-type="fig"}).

Figure 2Examples of BPE levels. Subtraction sagittal sequence showing minimal BPE (**A**), mild BPE (**B**), moderate BPE (**C**), and marked BPE (**D**).

Figure 3Examples of BPE symmetry. **A**: Axial subtraction showing symmetric BPE. **B**: Axial subtraction showing asymmetric BPE. The patient depicted was breastfeeding only from the right breast, with could explain the asymmetry.

Figure 4ROC curve for pCR. Area under the curve: 0.655; *p* = 0.001; 95% CI: 0.564-0.747. Cut-off point for pCR: ≤ 4.2.

Data analysis
-------------

The DCE-MRI data were paired with patient clinical issues, breast composition on mammography, tumor features (grade, immunohistochemical characteristics, and subtype), amount of fibroglandular tissue on MRI, features of BPE on MRI, and tumor size on MRI. The MRI assessment of both breasts included determining the amount of fibroglandular tissue, the level/symmetry of BPE, and the diameter of the tumor at its longest axis (for multicentric diseases, only the index lesion was considered).

All images were reviewed by the same radiologist, who had 10 years of experience in reading MRI scans and was blinded to all previous analyses. The results were classified and expressed as in the BI-RADS lexicon. Older examinations, performed prior to the release of the current edition of the BI-RADS, were reviewed and classified accordingly. The information about breast density on mammograms was collected directly from the database, without reassessment.

For comparison of categorical variables, we used the chi-square or Fisher's exact test. For comparison of numerical variables, we used the Mann-Whitney and Kruskal-Wallis tests. The level of significance adopted for the statistical tests was 5% (*p* \< 0.05).

RESULTS
=======

A total of 152 women met the criteria for inclusion. However, two were excluded because they had bilateral breast cancer. Therefore, the final sample comprised 150 women. The mean age was 45.2 years (range, 20-74 years). In each patient, both breasts presented similar results for all of the parameters analyzed.

Patients under 50 years of age presented higher pre-NAC BPE levels, in both breasts, than did those ≥ 50 years of age. [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"} show the demographic and clinical characteristics of the patients, together with the clinical characteristics of their affected and contralateral breasts, respectively, whereas [Tables 3](#t3){ref-type="table"} and [4](#t4){ref-type="table"} show the results of the univariate and multivariate analysis of data related to the affected and contralateral breasts, respectively. In the affected breast, 53.5% of the women under 50 years of age presented moderate or marked pre-NAC BPE, compared with only 13.7% of the women ≥ 50 years of age (odds ratio \[OR\] = 7.24; 95% confidence interval \[95% CI\]: 2.97-17.64). In the contralateral breast, those proportions were 51.5% and 11.7%, respectively (OR = 7.97; 95% CI: 3.12-20.37). Premenopausal women also showed higher BPE levels. In the affected breast, 50.5% of the premenopausal women presented moderate or marked pre-NAC BPE, compared with only 18.4% of the postmenopausal women (OR = 4.53; 95% CI: 1.99-10.31). In the contralateral breast, those proportions were 47.5% and 18.4%, respectively (OR = 4.03; 95% CI: 1.77-9.16).

###### 

Demographic and clinical characteristics of patients with unilateral breast cancer, together with the characteristics of the tumors in the affected breasts (n = 150).

  Characteristic                                            Affected breast[\*](#TFN1){ref-type="table-fn"}                                
  --------------------------------------------------------- ------------------------------------------------- --------------- ------------ -------------
  Age at dagnos s (years)                                                                                                                  
     \<40                                                   28 (31.1)                                         26 **(43.3)**   54 (36)       
     40-49                                                  18 (20.0)                                         27 **(45.0)**   45 (30)       
     ≥50                                                    44 **(48.9)**                                     7 (11.7)        51 (34)      **\<0.001**
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Menopausal status                                                                                                                        
     Premenopausal                                          50 (55.6)                                         51 **(85.0)**   101(67.3)     
     Postmenopausal                                         40 **(44.4)**                                     9 (15.0)        49 (32.7)    **\<0.001**
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Body mass index                                                                                                                          
     18.5-24.9 kg/m2 (normal-weight)                        34 (47.9)                                         26 (56.5)       60 (513)      
     25.0-29.9 kg/m2 (overweight)                           26 (36.6)                                         14 (30.4)       40 (34.2)     
     ≥30.0 kg/m^2^ (Obese)                                  11 (15.5)                                         6 (13.0)        17 (14.5)    0.659
     Total                                                  71 (100)                                          46 (100)        117 (100)     
  Tumor grade^[†](#TFN2){ref-type="table-fn"}^                                                                                             
     1                                                      3 (3.4)                                           1 (1-6)         4 (2.7)       
     2                                                      52 (60.2)                                         29 (47.5)       81 (555)      
     3                                                      32 (36.4)                                         29 (50.8)       61 (418)     0.359
     Total                                                  87 (100)                                          59 (100)        146 (100)     
  HER2 status                                                                                                                              
     Negative                                               65 (72.2)                                         40 (66.7)       105 (70.0)    
     Positive                                               25 (27.8)                                         20 (33.3)       45 (30.0)    0.467
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Estrogen receptor status                                                                                                                 
     Negative                                               40 (44.4)                                         27 (45.0)       67 (44.7)     
     Positive                                               50 (55.6)                                         33 (55.0)       83 (55.3)    0.947
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Progesterone receptor status                                                                                                             
     Negative                                               56 (62.2)                                         32 (53.3)       88 (58.7)     
     Positive                                               34 (37.8)                                         28 (46.7)       62 (41.3)    0.279
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Ki67 status                                                                                                                              
     Negative                                               27 (30.3)                                         21 (35.0)       48 (32.2)     
     Positive                                               62 (69.7)                                         39 (65.0)       101 (67.8)   0.550
     Total                                                  89 (100)                                          60 (100)        149 (100)     
  Tumor subtype                                                                                                                            
     Luminal A                                              14 (15.6)                                         12 (20.0)       26 (17.3)     
     Luminal B                                              24 (26.7)                                         11 (18.3)       35 (23.3)     
     HER2                                                   12 (13.3)                                         9 (15.0)        21 (14.0)     
     Luminal B HE32                                         13 (14.4)                                         11 (18.3)       24 (16.0)    0.772
     Tripie-negative                                        27 (30.0)                                         17 (28.3)       44 (29.4)     
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Fibroglandular tissue (on MRI)                                                                                                           
     Almost entirely fat                                    0                                                 1 (1-7)         1 (0.7)       
     Scattered fibroglanoular tissue                        67 (74.4)                                         30 (50.0)       97 (64.7)     
     Heterogeneous fibroglandular tissue                    22 (24.4)                                         25 (41.7)       47 (31.3)    **0.004**
     Extreme fibroglandular tissue                          1 (1.1)                                           4 (6.7)         5 (3.3)       
     Total                                                  90 (100)                                          60 (100)        150 (100)     
  Breast density (on mammography)                                                                                                          
     Almost entirely fat                                    3 (4.1)                                           0               3 (2.4)       
     Scattered areas of fibroglanduar density               41 (56.2)                                         23 (45.1)       64 (51.6)     
     Heterogeneously dense                                  28 (38.3)                                         23 (45.1)       51 (41.1)    0.051
     Extremer/ dense                                        1 (14)                                            5 (9.8)         6 (4.8)       
     Total                                                  73 (100)                                          51 (100)        124 (100)     
  Post-NAC change in BPE^[‡](#TFN3){ref-type="table-fn"}^                                                                                  
     Ncre or increase                                       49 (54.4)                                         3 (5.0)         52 (34.7)     
     Reduction                                              41 (45.6)                                         57 (95.0)       98 (65.3)    **\<0.001**
     Total                                                  90 (100)                                          60 (100)        150 (100)     

Bolding indicates significance.

Nottingham grading system.

After NAC, the BPE became symmetric in all cases and was marked in none.

###### 

Demographic and clinical characteristics of patients with unilateral breast cancer, together with the characteristics of the tumors of the contralateral breasts (n = 150).

  Characteristic                                            Contralate-al breast[\*](#TFN4){ref-type="table-fn"}                                
  --------------------------------------------------------- ------------------------------------------------------ --------------- ------------ --------------
  Age at diagnosis (years)                                                                                                                      
     \<40                                                   29 (31.2)                                              25 **(43.9)**   54 (36.0)     
     40-49                                                  19 (20.4)                                              26 **(45.6)**   45 (30.0)     
     ≥50                                                    45 **(48.4)**                                          6 (10.5)        51 (34.0)    **\< 0.001**
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Menopausal status                                                                                                                             
     Premenopausal                                          53 (57.0)                                              48 **(84.2)**   101 (67.3)    
     Postmenopausal                                         40 **(43.0)**                                          9 (15.8)        49 (32.7)    **\< 0.001**
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Body mass index                                                                                                                               
     18.5--24.9 kg/m2 (normal-weight)                       38 (48.7)                                              24 (55.8)       60 (51.3)     
     25.0-29.9 kg/m^2^ (overweight)                         26 (35.1)                                              14 (32.6)       40 (34.2)     
     ≥30.0 kg/m^2^ (ocese)                                  12 (18.2)                                              5 (11.6)        17 (14.5)    0.698
     Total                                                  74 (100)                                               43 (100)        117 (100)     
  Tumor grade^[†](#TFN5){ref-type="table-fn"}^                                                                                                  
     1                                                      3 (3.3)                                                1 (1-6)         4 (2.7)       
     2                                                      52 (58.9)                                              29 (49.2)       81 (55.5)     
     3                                                      34 (37.8)                                              27 (49.2)       61 (41.8)    0.539
     Total                                                  69 (100)                                               57 (100)        146 (100)     
  HER2 status                                                                                                                                   
     Negative                                               68 (73.1)                                              37 (64.9)       105 (70.0)    
     Positive                                               25 (28.9)                                              20 (35.1)       45 (30.0)    0.287
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Estrogen receptor status                                                                                                                      
     Negative                                               40 (42.1)                                              27 (45.8)       67 (44.7)     
     Positive                                               53 (57.9)                                              30 (54.3)       83 (55.3)    0.602
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Progesterone receptor status                                                                                                                  
     Negative                                               57 (81.3)                                              31 (54.4)       88 (58.7)     
     Positive                                               38 (38.7)                                              26 (45.6)       62 (41.3)    0.405
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Ki67 status                                                                                                                                   
     Negative                                               29 (31.5)                                              19 (33.3)       48 (32.2)     
     Positive                                               63 (68.5)                                              38 (66.7)       101 (67.8)   0.818
     Total                                                  89 (100)                                               57 (100)        149 (100)     
  Tumor subtype                                                                                                                                 
     Luminal A                                              15 (16.1)                                              11 (19.3)       26 (17.3)     
     Luminal B                                              26 (28.0)                                              9 (15.8)        35 (23.3)     
     HER2                                                   12 (12.9)                                              9 (15.8)        21 (14.0)     
     Luminal BHER2                                          13 (14.0)                                              11 (19.3)       24 (16.0)    0.511
     Triple-negatve                                         27 (29.0)                                              17 (29.8)       44 (29.4)     
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Fibroglandular tissue (on MRl)                                                                                                                
     Almost entirely fat                                    0                                                      1 (1-8)         1 (0.7)       
     Scattered fibroglandular tissue                        68 **(73.1)**                                          29 (50.9)       97 (64.7)     
     Heterogeneous fibroglandular tissue                    24 (25.8)                                              23 **(40.3)**   47 (31.3)    **0.008**
     Extreme fibroglandular tissue                          1(1.1)                                                 4 **(7.0)**     5 (3.3)       
     Total                                                  93 (100)                                               57 (100)        150 (100)     
  Breast density (on mammography)                                                                                                               
     Almost entirely fat                                    3 (4.0)                                                0               3 (2.4)       
     Scattered areas of fibroglandular density              41 (54.7)                                              23 (46.9)       64 (51.6)     
     Heterogeneously dense                                  30 (40.0)                                              21 (42.9)       51 (41.1)    0.069
     Extremely dense                                        1 (1-3)                                                5 (10.2)        6 (4.8)       
     Total                                                  75 (100)                                               49 (100)        124 (100)     
  Post-NAC charge in BPE^[‡](#TFN6){ref-type="table-fn"}^                                                                                       
     None or increase                                       52 **(55.9)**                                          3 (5.3)         55 (36.7)     
     Reduction                                              41 (44.1)                                              54 **(94.7)**   95 (63.3)    **\< 0.001**
     Total                                                  93 (100)                                               57 (100)        150 (100)     

Bolding indicates significance.

Nottingham grading system.

After NAC, the BPE became symmetric in all cases and was marked in none.

###### 

Univariate and multivariate logistic regression analysis of the BPE level in the affected breasts of patients with unilateral breast cancer.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                        Category                                      Univariate analysis[\*](#TFN8){ref-type="table-fn"}\           Stepwise multivariate analysis[\*](#TFN8){ref-type="table-fn"}\                             
                                                                                                (n = 150)                                                      (n = 137)                                                                                   
  ----------------------------------------------- --------------------------------------------- ------------------------------------------------------ ------- ----------------------------------------------------------------- --- ------------- ------- ------------
  Age at dagnoss (years)                          ≥ 50 (ref.)                                   \-                                                     1.00    \-                                                                    \-            1.00    \-

                                                  \<50                                          **\<0.001**                                            7.24    2.97-17.64                                                            **\<0.001**   6.88    2.45-19.34

  Body mass index                                 18.5-24.9 kgm^2^ (normal-weight, ref.)        \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  25.0-29.9 kg/m^2^ (overweight)                0.405                                                  0.70    0.31-1.61                                                             \-            \-      \-

                                                  ≥30.0 kg/m2 (obese)                           0.554                                                  0.71    0.23-2.18                                                             \-            \-      \-

  Menopausal status                               Postmenopausal (ref.)                         \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Premenopausal                                 **\<0.001**                                            4.53    1.99-10.31                                                            \-            \-      \-

  Breast density                                  Fat/scattered fibroglandular density (ref.)   \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Heterogeneously/extremely dense               0.097                                                  1.85    0.90-3.81                                                             \-            \-      \-

  Fibroglandular tissue                           Fat/scattered fibroglandular tissue (ref.)    \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Heterogeneous/extreme                         **0.005**                                              2.73    1.36-5.45                                                             \-            \-      \-

  Post-NAC change in BPE, affected breast         None or increase (ref.)                       ---                                                    1.00    ---                                                                   ---           1.00    ---

                                                  Reduction                                     **\<0.001**                                            22.70   6.62-77.88                                                            **\<0.001**   17.75   4.94-63.73

  Post-NAC change in BPE, contralateral breast    None or increase (ref.)                       \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Reduction                                     **\<0.001**                                            10.76   4.20-27.53                                                            \-            \-      \-

  Tumor grade^[§](#TFN11){ref-type="table-fn"}^   1 or 2 (ref.)                                 \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  3                                             0.138                                                  1.68    0.85-3.25                                                             \-            \-      \-

  Tumor subtype                                   Luminal B (ref.)                              \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Luminal A                                     0.243                                                  1.87    0.65-5.35                                                             \-            \-      \-

                                                  HER2+ or Luminal B HER2+                      0.238                                                  1.75    0.69-4.40                                                             \-            \-      \-

                                                  Triple-negative                               0.507                                                  1.37    0.54-3.51                                                             \-            \-      \-

  Estrogen receptor status                        Negative (ref.)                               \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Positive                                      0.947                                                  0.98    0.51-1.89                                                             \-            \-      \-

  Progesterone receptor status                    Negatve (ref.)                                \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Positive                                      0.280                                                  144     0.74-2.80                                                             \-            \-      \-

  HER2 status                                     Negative (ref.)                               \-                                                     1.00    \-                                                                    \-            \-      \-

                                                  Positive                                      0.468                                                  1.30    0.64-2.64                                                             \-            \-      \-

  Ki67 status                                     Negative (ref.)                               ---                                                    1.00    ---                                                                   ---           \-      ---

                                                  Positive                                      0.551                                                  0.81    0.40-1.62                                                             \-            \-      \-

  Clinical pre-NAC tumor size                     Continuous variable                           0.703                                                  0.964   0.798-1.165                                                           \-            \-      \-

  Ultrasound pre-NAC tumor size                   Continuous variable                           0.183                                                  0.860   0.690-1.073                                                           \-            \-      \-

  MRI pre-NAC tumor size                          Continuous variable                           0.598                                                  0.9S8   0.816-1.124                                                           \-            \-      \-
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ref., reference.

Bolding indicates significance.

For moderate/marked pre-NAC BPE (n = 56) vs. minimal/mild pre-NAC BPE (n = 81).

For moderate/marked pre-NAC BPE (n = 60) vs. minimal/mild pre-NAC BPE (n = 90).

Nottingham grading system.

###### 

Univariate and multivariate logistic regression analysis of the BPE level in the contralateral breasts of patients with unilateral breast cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                        Category                                      Univariate analysis[\*](#TFN13){ref-type="table-fn"}\           Stepwise multivariate analysis[\*](#TFN13){ref-type="table-fn"}\                             
                                                                                                (n = 150)                                                       (n = 137)                                                                                    
  ----------------------------------------------- --------------------------------------------- ------------------------------------------------------- ------- ------------------------------------------------------------------ --- ------------- ------- ------------
  Age at diagnosis (years)                        ≥ 50 (ref.)                                   ---                                                     1.00    ---                                                                    ---           1.00    ---

                                                  \<50                                          **\<0.001**                                             7.97    3.12-20.37                                                             **\<0.001**   6.55    2.32-18.46

  Body mass index                                 18.5-24.9 kg/m2 (normal-weight, ref.)         \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  25.0-29.9 kg/m^2^ (overweight)                0.614                                                   0.81    0.35-1.85                                                              \-            \-      \-

                                                  ≥ 30.0 kg\'m^2^ (obese)                       0.429                                                   0.63    0.20-2.00                                                              \-            \-      \-

  Menopausal status                               Postmenopausal (ref.)                         \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Premenopausal                                 **\<0.001**                                             4.03    1.77-9.16                                                              \-            \-      \-

  Breast density                                  Fat/scattered fibroglandular density (ref.)   \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Heterogeneously/extremely dense               0.201                                                   1.60    0.78-3.31                                                              \-            \-      \-

  Fibroglandular tissue                           Fat/scattered fibroglandular tissue (ref.)    \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Heterogeneous/extreme                         **0.011**                                               2.45    1.22-4.90                                                              \-            \-      \-

  Post-NAC change in BPE, affected breast         None or increase (ref.)                       \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Reduction                                     **\<0.001**                                             20.04   585-68.66                                                              \-            \-      \-

  Post-NAC change in BPE, contralateral breast    None or increase (ref.)                       \-                                                      1.00    \-                                                                     \-            1.00    \-

                                                  Reduction                                     **\<0.001**                                             22.83   6.66-78.30                                                             **\<0.001**   18.57   5.19-68.49

  Tumor grade^[§](#TFN16){ref-type="table-fn"}^   1 or 2 (ref.)                                 \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  3                                             0.274                                                   1.46    0.74-2.85                                                              \-            \-      \-

  Tumor subtype                                   Luminal B (ref.)                              \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Luminal A                                     0.176                                                   2.12    0.72-628                                                               \-            \-      \-

                                                  HER2+ or Luminal B HER2+                      0.087                                                   2.31    0.89-6.03                                                              \-            \-      \-

                                                  Triple-negative                               0.227                                                   1.82    0.69-4.80                                                              \-            \-      \-

  Estrogen receptor status                        Negative (ref.)                               \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Positive                                      0.603                                                   0.84    0.43-L63                                                               \-            \-      \-

  Progesterone receptor status                    Negative (ref.)                               \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Positive                                      0.405                                                   1.33    0.68-2.59                                                              \-            \-      \-

  HER2 status                                     Negative (ref.)                               \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Positive                                      0.288                                                   1.47    0.72-3.00                                                              \-            \-      \-

  Ki67 status                                     Negative (ref.)                               \-                                                      1.00    \-                                                                     \-            \-      \-

                                                  Positive                                      0.818                                                   0.92    0.46-1.86                                                              \-            \-      \-

  Clinical pre-NAC tumor size                     Continuous variable                           0.420                                                   0.923   0.759-1.22                                                             \-            \-      \-

  Ultrasound pre-NAC tumor size                   Continuous variable                           0.287                                                   0.887   0.711-1.106                                                            \-            \-      \-

  MRI pre-NAC tumor size                          Continuous variable                           0.267                                                   0.911   0.773-1.074                                                            ---           ---     ---
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ref., reference.

Bolding indicates significance.

For moderate/marked pre-NAC BPE (n = 56) vs. minimal/mild pre-NAC BPE (n = 81).

For moderate/marked pre-NAC BPE (n = 60) vs. minimal/mild pre-NAC BPE (n = 90).

Nottingham grading system.

The univariate analysis showed that, for the affected breasts, 25.5% of the women who had low pre-NAC BPE levels presented heterogeneous or extreme fibroglandular tissue, whereas 48.4% of those who had high pre-NAC BPE levels presented such tissue (OR = 2.73; 95% CI: 1.36-5.45), as can be seen in [Tables 1](#t1){ref-type="table"} and [3](#t3){ref-type="table"}. For the contralateral breasts, 26.9% of the women who had low pre-NAC BPE levels presented heterogeneous or extreme fibroglandular tissue, whereas 47.3% of those who had high pre-NAC BPE levels presented these patterns (OR = 2.45; 95% CI: 1.22-4.90), as can be seen in [Tables 2](#t2){ref-type="table"} and [4](#t4){ref-type="table"}. The proportion of affected breasts showing a post-NAC reduction in BPE was 95.0% for those presenting high pre-NAC BPE levels and 45.6% for those presenting low pre-NAC BPE levels (OR = 22.7; 95% CI: 6.62-77.86). For the contralateral breasts, those proportions were 94.7% and 44.1%, respectively (OR = 20.04; 95% CI: 5.85-68.66).

In the multivariate regression analysis, only being under 50 years of age and a post-NAC reduction in BPE were independently correlated with a high pre-NAC BPE level in both breasts. In the affected breasts ([Table 3](#t3){ref-type="table"}), being under 50 years of age showed an OR of 6.55 (95% CI: 2.32-18.46) and a post-NAC reduction in BPE showed an OR of 17.75 (95% CI: 4.94-63.73).

In the contralateral breasts ([Table 4](#t4){ref-type="table"}), being under 50 years of age showed an OR of 6.55 (95% CI: 2.32-18.46) and a post-NAC reduction in BPE showed an OR of 18.47 (95% CI: 5.19-66.49). The pre-NAC BPE level was not found to correlate with body mass index, breast density, tumor grade, estrogen receptor status, progesterone receptor status, HER2 status, Ki67 status, or tumor subtype. When adjusted for the pre-NAC tumor size on MRI, luminal subtype, age, tumor grade, and menopausal status, the multivariate analysis also showed that a pre-NAC reduction in BPE, in the affected or contralateral breast, was an independent predictor of achieving a pCR ([Table 5](#t5){ref-type="table"}).

###### 

Multivariate logistic regression of factors associated with achieving a pCR, adjusted for pre-NAC tumor size on MRI, luminal subtype, patient age, tumor grade, and menopausal status in patients with unilateral breast cancer (n = 146).

  variable                                       Category                       *P*[\*](#TFN17){ref-type="table-fn"}   OR^[†](#TFN18){ref-type="table-fn"}^   95% Cl
  ---------------------------------------------- ------------------------------ -------------------------------------- -------------------------------------- -------------
  Symmetry of pre-NAC BPE                        Asymmetric (reference)         \-                                     1.00                                   \-
                                                 Symmetric                      0.316                                  4.21                                   0.11-15L98
  Level of pre-NAC BPE, affected breast          Minimal (reference)            \-                                     1.00                                   \-
                                                 Mild                           0.728                                  1.19                                   0.44-3.22
                                                 Moderate                       0.375                                  1.66                                   0.54-5.04
                                                 Marked                         0.829                                  0.87                                   0.24-3.13
  Level of pre-NAC BPE, contralateral breast     Minimal (reference)            \-                                     1.00                                   \-
                                                 Mild                           0.811                                  1.13                                   0.42-3.04
                                                 Moderate                       0.302                                  1.80                                   0.59-5.53
                                                 Marked                         0.919                                  0.94                                   0.26-3.41
  Post-NAC change in BPE, affected breast        None or increase (reference)   \-                                     1.00                                   \-
                                                 Reduction                      **0.007**                              2.94                                   1.34 - 6.42
  Post-NAC change in BPE, contralateral breast   None or increase (reference)   \-                                     1.00                                   \-
                                                 Reduction                      **0.003**                              3.19                                   1.48-6.91

Bolding indicates significance.

For achieving a pCR (n = 67) vs. not achieving a pCR (n = 79).

DISCUSSION
==========

In addition to tumor enhancement on breast MRI, which has been shown to be an important marker of a response to NAC, another component, BPE, also appears to be a useful parameter in patients with unilateral breast cancer undergoing NAC. Müller-Schimpfle et al.^([@r15])^ studied BPE variation during the menstrual cycle and its relationship with age. The authors found that the level of BPE was higher in patients between 35 and 50 years of age than among those who were younger or older. They also showed that postmenopausal women typically have a lower level of BPE than do premenopausal women.

In the present study, being under age 50 and having a post-NAC reduction in BPE were independently correlated with a higher pre-NAC BPE level, in both breasts. Both of those factors are clearly correlated with hormonal status, as has previously been reported^([@r11],[@r15]-[@r19])^. Therefore, we can extrapolate a correlation between hormonal status and higher BPE. This suggests that the breasts of premenopausal women have greater vascularization, greater permeability to the contrast agent, or both.

Schrading et al.^([@r20])^studied the influence of taxanes on the response assessment with DCE-MRI and showed that even the normal (contralateral) breasts present modifications after NAC. The ovarian suppression caused by chemotherapy could explain their findings, at least in part.

Chen et al.^([@r8])^ also found that higher BPE before NAC in contralateral breasts was associated with a greater reduction in BPE after the treatment. It should be borne in mind that all of this behavior occurs bilaterally. Although this might have been supposed, confirmatory data were not yet available, because all previous studies of the topic involved only women without cancer or only the contralateral breast of women with unilateral invasive cancer^([@r7],[@r8],[@r20]-[@r23])^. Our findings allow us to conclude that the behavior of BPE is unaffected by the presence of the tumor in the affected breast or by the absence of a tumor in the contralateral breast. The lack of data from affected breasts is notable, because of the possibility of misinterpretation between parenchymal and tumor enhancement. The similarity presented in our study supports a variety of translational possibilities.

Diffuse BPE, if it is moderate or marked, may interfere with the accuracy of DCE-MRI, reducing its capacity to detect small lesions^([@r19],[@r24])^. In the present study, neither breast density nor the histopathological features of the tumor correlated with BPE levels, supporting the idea that BPE could be an imaging biomarker of a response to NAC that is independent of tumor features.

When the BPE is asymmetrical, it may be confused with non-mass enhancement, mostly when it appears as regional or focal. Baltzer et al.^([@r25])^ found that lesions with non-mass-like enhancement were the main cause of falsepositive findings leading to biopsy. Only four of the 150 women in our sample presented with diffuse asymmetric BPE, which became symmetric after NAC in all four.

A number of studies have shown that BPE changes throughout the menstrual cycle, being less intense and more diffuse in the second week^([@r15],[@r16],[@r19])^. Because of the urgency of the cases in our sample, the stage of the menstrual cycle was not taken into account in the scheduling of the examinations, which constitutes a limitation of our study.

It is noteworthy that we found considerable similarity between the affected and contralateral breasts. Contrary to previous suppositions, our data show that the presence of a tumor does not alter BPE. That allows BPE to be used as a marker of a response to NAC, even in cases of bilateral breast cancer or contralateral mastectomy.
